Question 1

What is combined oxidative phosphorylation defect type 26?

Accepted Answer

Combined oxidative phosphorylation defect type 26 is a multisystem disorder caused by pathogenic variants in the TRMT5 gene that impair mitochondrial function. Individuals with this condition typically exhibit a range of features including muscle weakness, lactic acidosis, and liver cirrhosis. It is inherited in an autosomal recessive pattern, which means that a person must inherit two copies of the mutated gene to be affected. This condition is very rare, affecting fewer than 1 in 1,000,000 people, and early signs such as exercise intolerance and spasticity may develop in infancy or early childhood.

Question 2

What are the symptoms of combined oxidative phosphorylation defect type 26?

Accepted Answer

The clinical presentation of combined oxidative phosphorylation defect type 26 involves several characteristic features. Nearly all affected individuals show increased circulating lactate, lactic acidosis, cirrhosis, spasticity, exertional dyspnea, muscle weakness, and exercise intolerance. Neurological involvement is also noted, with many individuals experiencing poor speech and global developmental delay, along with brain atrophy seen in some cases. Other variable manifestations include renal tubular dysfunction, hypertonia, difficulty standing, malabsorption, feeding difficulties, narrow mouth, blue sclerae, and 2-3 toe syndactyly. Not all individuals experience all features, and severity varies considerably.

Question 3

What causes combined oxidative phosphorylation defect type 26?

Accepted Answer

Combined oxidative phosphorylation defect type 26 is caused by pathogenic variants in the TRMT5 gene, which is critical for proper mitochondrial function. The condition follows an autosomal recessive inheritance pattern, meaning that affected individuals inherit a mutated copy of TRMT5 from each parent. It is more common when parents share a common ancestor, as this increases the likelihood that both carry the same rare genetic variant. Genetic counseling is recommended for families to understand recurrence risks and explore family planning options. Associated genes include TRMT5.

Question 4

How is combined oxidative phosphorylation defect type 26 inherited?

Accepted Answer

combined oxidative phosphorylation defect type 26 follows an autosomal recessive inheritance pattern. This means a child must inherit a copy of the altered gene from both parents to develop the condition. Parents who each carry one copy typically do not show symptoms.

Question 5

How rare is combined oxidative phosphorylation defect type 26?

Accepted Answer

combined oxidative phosphorylation defect type 26 is classified as very rare. The estimated prevalence is approximately <1 in 1,000,000. Because rare disease data can be limited, actual numbers may differ from published estimates.

Question 6

How is combined oxidative phosphorylation defect type 26 diagnosed?

Accepted Answer

Diagnosis is confirmed through molecular genetic testing that identifies pathogenic variants in the TRMT5 gene. A thorough clinical evaluation—focusing on features such as elevated lactate levels, cirrhosis, and muscle weakness—also supports the diagnosis. Because many of these symptoms can overlap with other conditions, genetic testing is essential to distinguish this disorder from similar conditions.

Question 7

Are there treatments for combined oxidative phosphorylation defect type 26?

Accepted Answer

Currently, management focuses on supportive care and symptom control, as there are no treatments specifically approved for combined oxidative phosphorylation defect type 26. Care is typically provided by a multidisciplinary team that addresses respiratory difficulties, muscle weakness, feeding challenges, and liver dysfunction. Regular surveillance is an essential part of long-term care and helps to identify emerging complications at an early stage. Patients should discuss treatment options with their healthcare team and consider genetic counseling to help guide care decisions.

Question 8

What complications should we watch for with combined oxidative phosphorylation defect type 26?

Accepted Answer

With combined oxidative phosphorylation defect type 26, complications can affect multiple organ systems. Patients may experience issues like muscle weakness, respiratory difficulties, and liver dysfunction. Regular check-ups are important to catch any new problems early and manage them effectively.

Question 9

How does combined oxidative phosphorylation defect type 26 affect daily life for patients?

Accepted Answer

Daily life for patients with combined oxidative phosphorylation defect type 26 can be challenging due to symptoms like muscle weakness and exercise intolerance. Many may need help with activities that require physical strength, and some may have feeding difficulties. Supportive care and a multidisciplinary team can help improve quality of life.

Question 10

What is the prognosis for someone with combined oxidative phosphorylation defect type 26?

Accepted Answer

The prognosis for individuals with combined oxidative phosphorylation defect type 26 varies widely. Some patients manage their symptoms well with current care, while others may face serious complications. It's important for families to work closely with specialists to monitor health and adjust care as needed.

Question 11

Are there specific specialists we should consult for combined oxidative phosphorylation defect type 26?

Accepted Answer

Families dealing with combined oxidative phosphorylation defect type 26 should consider consulting a team of specialists. This may include geneticists, neurologists, and metabolic specialists who understand the condition. A multidisciplinary approach can help address the various challenges that arise from this disorder.

Kisho

combined oxidative phosphorylation defect type 26

Overview

Clinical Presentation

Genetic Landscape

Diagnosis

Prognosis

Research Landscape

Recent Publications

Medical References

External Resources

OMIM

Orphanet

GARD

Questions for Your Care Team

Questions for Your Care Team

FAQ

Frequently Asked Questions

Explore clinical features

combined oxidative phosphorylation defect type 26

Overview

Clinical Presentation

Genetic Landscape

Diagnosis

Prognosis

Research Landscape

Recent Publications

Medical References

External Resources

OMIM

Orphanet

GARD

Related Diseases

Questions for Your Care Team

Questions for Your Care Team

FAQ

Frequently Asked Questions

What is combined oxidative phosphorylation defect type 26?

What are the symptoms of combined oxidative phosphorylation defect type 26?

What causes combined oxidative phosphorylation defect type 26?

How is combined oxidative phosphorylation defect type 26 inherited?

How rare is combined oxidative phosphorylation defect type 26?

How is combined oxidative phosphorylation defect type 26 diagnosed?

Are there treatments for combined oxidative phosphorylation defect type 26?

What complications should we watch for with combined oxidative phosphorylation defect type 26?

How does combined oxidative phosphorylation defect type 26 affect daily life for patients?

What is the prognosis for someone with combined oxidative phosphorylation defect type 26?

Are there specific specialists we should consult for combined oxidative phosphorylation defect type 26?

Explore clinical features